BeiGene exploring commercialization options for returned PD-1 inhibitor

After regaining global rights to PD-1 inhibitor tislelizumab from Celgene, BeiGene is exploring options to commercialize the asset on its own or find a partner for the product in the U.S., Europe and Japan. The deal termination came as no surprise to BeiGene, and doesn't shift its global development strategy given the advanced stage of the deal and trials.

In

Read the full 608 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE